tirzepatide cardiovascular outcomes trial 💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT found that was noninferior to dulaglutide for major events (12.2% vs 13.1%; HR 0.92). What SUMMIT: Tirzepatide Improves Outcomes and

For those who cant give up the fizz of soda, she recommends naturally flavored carbonated waters instead

Depends on your research question

Dosing Guidelines : If considering BPC 157, experts suggest taking the minimal effective dose (300-500 mcg, two to three times per week) and monitoring for any adverse effects related to potential tumor growth 1 4

She shared on "The Kelly Clarkson Show" in 2022 that it forced her to accept herself early on

Kjeldsen SAS, Richter MM, Jensen NJ et al (2023) Development of a glucagon sensitivity test in humans: pilot data and the GLUSENTIC study protocol

Like any intervention, it comes with trade-offs worth understanding